Table 1 Patients demographics
From: The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Patient characteristics | N=8 | % |
|---|---|---|
Gender | ||
 Male | 3 | 37.5 |
 Female | 5 | 62.5 |
Age (Median, IQR) years | 36.0 (10.2, 61.8) | Â |
Location of primary lesion | ||
 Trunk | 0 | 0.0 |
 Upper extremities | 4 | 50.0 |
 Lower extremities | 3 | 37.5 |
 Other sites | 1 | 12.5 |
INI 1 loss | ||
 Yes | 7 | 87.5 |
 No | 0 | 0.0 |
 Not known | 1 | 12.5 |
ECOG score | ||
 0–2 | 7 | 87.5 |
 > 2 | 1 | 12.5 |
Stage at initial diagnosis | ||
 Localized (including local tumor thrombosis and lymphatic metastasis) | 5 | 62.5 |
 Metastatic | 3 | 37.5 |
Location of metastatic lesions | ||
 Lung | 0 | 0.0 |
 Lymph nodes | 3 | 60.0 |
 Multiple organ metastasis | 2 | 40.0 |
Lines of previous systemic therapy | ||
 0 line | 2 | 25.0 |
 1 line | 1 | 12.5 |
 2 lines | 4 | 50.0 |
 3 lines and more | 1 | 12.5 |
Best overall response | ||
 PR | 3 | 37.5 |
 SD | 5 | 62.5 |
 PD | 0 | 0.0 |
PFS (Mean, 95%CI) months | 8,2 (8.0, 8.3) | Â |
OS (Mean, 95%CI) months | 74.8 (54.1, 95.4) | Â |